These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 19296538

  • 1. FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.
    Falvella FS, Frullanti E, Galvan A, Spinola M, Noci S, De Cecco L, Nosotti M, Santambrogio L, Incarbone M, Alloisio M, Calabrò E, Pastorino U, Skaug V, Haugen A, Taioli E, Dragani TA.
    Int J Cancer; 2009 Jun 15; 124(12):2880-5. PubMed ID: 19296538
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma.
    Choi KY, Rho YS, Kwon KH, Chung EJ, Kim JH, Park IS, Lee DJ.
    Cancer Biomark; 2009 Jun 15; 12(3):115-24. PubMed ID: 23481570
    [Abstract] [Full Text] [Related]

  • 6. Further observations on the relationship between the FGFR4 Gly388Arg polymorphism and lung cancer prognosis.
    Matakidou A, El Galta R, Rudd MF, Webb EL, Bridle H, Eisen T, Houlston RS.
    Br J Cancer; 2007 Jun 18; 96(12):1904-7. PubMed ID: 17519899
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor.
    Frullanti E, Berking C, Harbeck N, Jézéquel P, Haugen A, Mawrin C, Parise O, Sasaki H, Tsuchiya N, Dragani TA.
    Eur J Cancer Prev; 2011 Jul 18; 20(4):340-7. PubMed ID: 21412156
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J, Izumo T, Hirano M, Oyazato Y, Hori F, Umemura E, Shisa H, Hiai H, Kitano M.
    Oncol Rep; 2010 Mar 18; 23(3):739-44. PubMed ID: 20127014
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.
    da Costa Andrade VC, Parise O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B.
    Exp Mol Pathol; 2007 Feb 18; 82(1):53-7. PubMed ID: 17084840
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
    Quintanal-Villalonga Á, Carranza-Carranza A, Meléndez R, Ferrer I, Molina-Pinelo S, Paz-Ares L.
    Clin Lung Cancer; 2017 Nov 18; 18(6):667-674.e1. PubMed ID: 28583379
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.